JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

Sanofi

Cerrado

51.62 4.07

Resumen

Variación precio

24h

Actual

Mínimo

51.44

Máximo

51.86

Métricas clave

By Trading Economics

Ingresos

2.1B

3.9B

Ventas

129M

11B

P/B

Media del Sector

16.577

37.461

BPA

0.91

Rentabilidad por dividendo

7.74

Margen de beneficio

36.702

Empleados

82,878

EBITDA

-881M

1.9B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+21.03% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

7.74%

2.33%

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

1.4B

123B

Apertura anterior

47.55

Cierre anterior

51.62

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Sanofi Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

24 oct 2025, 08:29 UTC

Ganancias

Sanofi Earnings Get Boost From Dupixent, New Drugs as U.S. Talks Continue -- Update

24 oct 2025, 07:00 UTC

Ganancias

Sanofi Earnings Driven by New Medicine Sales, Dupixent Performance

1 oct 2025, 08:54 UTC

Principales Movimientos del Mercado

Pharma Stocks in Europe Jump After White House Unveils Drug-Buying Site

4 sept 2025, 08:58 UTC

Principales Movimientos del Mercado

Sanofi Shares Sink as Experimental Drug Results Disappoint

31 jul 2025, 06:00 UTC

Ganancias

Sanofi Upbeat on Sales Outlook After Faster-Than-Expected Growth

24 oct 2025, 08:21 UTC

Charlas de Mercado
Ganancias

Sanofi Results Reflect Improved Efficiency, Should Ease Margin Worries -- Market Talk

24 oct 2025, 07:56 UTC

Charlas de Mercado
Ganancias

Sanofi's Dupixent Drives Growth, But Lantus Gains Set to Fade -- Market Talk

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Adj EPS EUR2.91

24 oct 2025, 05:30 UTC

Ganancias

Sanofi Backs 2025 View

24 oct 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Business Net Profit at EUR3.29B

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Business Net Profit at EUR3.55B

24 oct 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Adjusted EPS at EUR2.70

24 oct 2025, 05:30 UTC

Ganancias

Sanofi: Dupixent Sales Up 26% to EUR4.16B

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Net Pft EUR2.80B

24 oct 2025, 05:30 UTC

Ganancias

Analysts Saw Sanofi 3Q Net Sales at EUR12.29B

24 oct 2025, 05:30 UTC

Ganancias

Sanofi 3Q Sales EUR12.43B

6 oct 2025, 08:15 UTC

Charlas de Mercado

Sanofi's Profitability Stronger Than It Looks -- Market Talk

3 oct 2025, 14:10 UTC

Charlas de Mercado

Sanofi Sales Could Miss Forecasts, With Adjusted Profit in Line -- Market Talk

1 oct 2025, 07:53 UTC

Charlas de Mercado

Pfizer's U.S. Pricing Move Brings Clarity for Pharma Sector -- Market Talk

5 sept 2025, 08:24 UTC

Charlas de Mercado

Sanofi's Eczema Drug Candidate Could Still Become a Blockbuster -- Market Talk

5 sept 2025, 06:55 UTC

Charlas de Mercado

Sanofi Share Fall After Eczema Trial Results Looks Overdone -- Market Talk

6 ago 2025, 05:02 UTC

Adquisiciones, fusiones, absorciones

Sanofi Completes the Acquisition of Vigil Neuroscience

6 ago 2025, 05:00 UTC

Adquisiciones, fusiones, absorciones

Press Release: Sanofi Completes The Acquisition Of Vigil Neuroscience, Inc. >SAN.FR

1 ago 2025, 13:16 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

1 ago 2025, 12:40 UTC

Ganancias

Regeneron Stock Is Rising on Earnings. This Sanofi Collaboration Is Helping. -- Barrons.com

31 jul 2025, 08:15 UTC

Charlas de Mercado
Ganancias

Sanofi's Higher Costs Take Shine off Outlook Raise -- Market Talk

31 jul 2025, 05:56 UTC

Charlas de Mercado
Ganancias

Sanofi in the Dark on Pharma Tariffs After U.S.-EU Deal -- Market Talk

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Vaccine Sales Increased 10% to EUR1.2B

31 jul 2025, 05:30 UTC

Ganancias

Sanofi Says Pharma Launches Sales Increased by 40% in 2Q

31 jul 2025, 05:30 UTC

Ganancias

Sanofi 2Q Dupixent Sales Grew 21% to EUR3.8B

Comparación entre iguales

Cambio de precio

Sanofi Esperado

Precio Objetivo

By TipRanks

21.03% repunte

Estimación a 12 meses

Media 62.5 USD  21.03%

Máximo 67 USD

Mínimo 58 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sanofi Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

3 ratings

3

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

51.665 / 52.38Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Weak Bullish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
help-icon Live chat